Clinical TrialsRisks include failure of KIO-301 in clinical trials and failure to secure regulatory approval.
Financial PerformanceFor 4Q24, net loss was $4.2M, higher than the estimated loss of $2.7M.
Market CompetitionRisks include the failure of KIO-301 in clinical trials, to secure regulatory approval, or to achieve commercial success due to reimbursement, penetration rate, and competition.